-
Electroconvulsive therapy in a patient with Huntington's disease and depression: a case-report
Tijdschr Psychiatr. 2026;68(2):82-85.ABSTRACTWe present the case of a 60-year-old woman with Huntington’s disease who was successfully treated with electroconvulsive therapy (ECT) for a recurrent depressive disorder presenting with acute suicidality. Depression is the most common neuropsychiatric disorder in Huntington’s disease and ranks among the most important risk factors for suicide...Read more
-
Ubiquitin ligase Nedd4 regulates the abundance and toxicity of mutant huntingtin
JCI Insight. 2026 Feb 23;11(4):e181013. doi: 10.1172/jci.insight.181013. eCollection 2026 Feb 23.ABSTRACTHuntington's disease (HD) is a neurodegenerative disorder caused by the expansion of CAG repeats in the gene encoding huntingtin. Since accumulation of mutant huntingtin (mHtt) leads to dysfunction of numerous cellular pathways and toxicity, reducing levels of the mutant protein...Read more
-
Differences in white matter detected by ex vivo 9.4 T MRI are associated with axonal changes in the R6/1 model of Huntington's disease
Neurobiol Dis. 2026 Mar;220:107318. doi: 10.1016/j.nbd.2026.107318. Epub 2026 Feb 11.ABSTRACTWhite matter volume loss has been reported as one of the first indicators in Huntington's disease (HD) patients, but the cellular basis of this deficit remains to be elucidated. To address this, we assessed white matter microstructure in the transgenic R6/1...Read more
-
Decreased Physical Activity as an Early Digital Biomarker in Huntington's Disease: A One-Year Observational Study
Brain Behav. 2026 Feb;16(2):e71149. doi: 10.1002/brb3.71149.ABSTRACTINTRODUCTION: Huntington's disease (HD) is a neurodegenerative disorder characterised by motor dysfunction, cognitive impairment, and psychiatric disturbances. This study analyzed the relationship between clinical characteristics, sarcopenia, and physical activity (PA) levels in HD patients.METHODS: A 1-year observational study was conducted with symptomatic, ambulatory HD patients,...Read more
-
Co-Design of a New Integrated Care Model With People Affected by Huntington's Disease: A Mixed Methods Study
Health Expect. 2026 Feb;29(1):e70584. doi: 10.1111/hex.70584.ABSTRACTBACKGROUND: People living with neurological conditions have needs that require an integrated care approach. Existing models of integrated care have often emphasized system structures but neglected the micro-level interactions that matter most to people.OBJECTIVES: To develop a micro-level model for integrated care that represents the...Read more
-
Executive Impairment in Huntington's Disease: Insights From a Systematic Review of the Literature
Brain Behav. 2026 Feb;16(2):e71238. doi: 10.1002/brb3.71238.ABSTRACTPURPOSE: This systematic review examines executive dysfunction in Huntington's disease (HD), an inherited neurodegenerative disorder characterized by cognitive alterations that may emerge years before the onset of motor symptoms. The objective of this review is to provide an updated and comprehensive synthesis of executive function...Read more
-
Exploring huntington's disease from a neurodevelopmental perspective
Int J Biol Sci. 2026 Jan 1;22(3):1233-1246. doi: 10.7150/ijbs.124552. eCollection 2026.ABSTRACTHuntington's disease (HD) is a rare, inherited neurodegenerative disorder caused by mutations in the huntingtin (HTT) gene. The classic concept is that HD is a degenerative disease that primarily affects the striatum, caused by a gain-of-function mutant mHTT that kills...Read more
-
Non-Directiveness and Authenticity in the Predictive Genetic Clinic
Sociol Health Illn. 2026 Feb;48(2):e70149. doi: 10.1111/1467-9566.70149.ABSTRACTThe predictive genetic clinic is a space where counsellors use non-directive counselling to facilitate asymptomatic patients at risk of carrying a dominantly inherited disease access a predictive genetic test. The social science literature has a history of examining practices within this clinic, but with...Read more
-
From Cancer to Neuroprotection: Pazopanib Modulates the RIPK1/RIPK3/MLKL and PGAM5/DRP1 Pathways in 3- Nitropropionic Acid-Induced Huntington's Disease
Drug Dev Res. 2026 Apr;87(2):e70238. doi: 10.1002/ddr.70238.ABSTRACTHuntington's disease (HD) is a progressive neurodegenerative disorder with a poorly understood neurobiological basis. Among the various forms of programmed cell death implicated in neurodegeneration, necroptosis has recently garnered significant attention. Notably, dysregulated necroptosis provokes immune response that drives excessive pro-inflammatory cytokine production, promoting...Read more
-
Shape matters: Predicting Huntington's disease using progression modelling
Comput Methods Programs Biomed. 2026 Apr;277:109250. doi: 10.1016/j.cmpb.2026.109250. Epub 2026 Jan 15.ABSTRACTBACKGROUND: Despite evidence of group-level differences in striatal morphometry among persons with Huntington's Disease (PwHD), current models of HD progression used for participant selection and assessment of treatment outcomes in clinical trials do not leverage shape information.METHODS: We first...Read more
-
Decoding Non-Neuronal Mechanisms and Therapeutic Targets in Huntington's Disease Through Integrative Transcriptomics and Machine Learning
J Mol Neurosci. 2026 Jan 19;76(1):11. doi: 10.1007/s12031-025-02463-z.ABSTRACTHuntington's disease (HD) is a rare, inherited neurodegenerative disorder caused by the expanded CAG repeats in the huntingtin gene. The HD domain still lacks detailed knowledge of validated drug targets, limiting the effectiveness of classical methods. To address this gap, we have applied...Read more
-
Astrocytic noncanonical WNT5B signaling modulates extracellular matrix remodeling and neuropathology in Huntington's disease
Signal Transduct Target Ther. 2026 Jan 19;11(1):23. doi: 10.1038/s41392-025-02545-9.ABSTRACTHuntington's disease (HD) is a fatal neurodegenerative disorder characterized by a triad of behavioral symptoms: involuntary movement, emotional change, and cognitive dysfunction. Although alterations in WNT signaling have been reported in HD, its precise role in pathogenesis remains unclear. In this study,...Read more
-
Discovery of disrupted sustained attention and altered functional connectivity in far-from-onset Huntington's disease gene-expanded young adults
Alzheimers Dement. 2026 Jan;22(1):e70944. doi: 10.1002/alz.70944.ABSTRACTBACKGROUND: Cognitive impairments are a hallmark of Huntington's disease (HD).METHODS: Seventy-one participants (43 HD gene-expanded [HDGE], 28 healthy controls) from the HD-Young Adult Study at two timepoints ≈ 4.7 years apart, completed the Cambridge Neuropsychological Test Automated Battery Rapid Visual Information Processing task and underwent...Read more
-
Eye manifestations in Huntington's disease: an update on the potential of ocular biomarkers
J Neurol. 2026 Jan 8;273(1):68. doi: 10.1007/s00415-025-13600-4.ABSTRACTHuntington's disease (HD) remains a devastating neurodegenerative disorder caused by CAG repeat expansion in the HTT gene. Biomarkers are urgently needed to facilitate more accurate evaluation of disease onset, progression, and response to interventions. Characteristic clinical features of the disease are secondary to neuronal...Read more
-
Programmed cell death pathways in huntington's disease: spotlight on ferroptosis and pyroptosis
Neurol Sci. 2026 Jan 2;47(1):83. doi: 10.1007/s10072-025-08689-4.ABSTRACTHuntington's disease (HD) is characterized by dementia, delayed psychomotor processes, abnormal choreatic movements, and cognitive impairments. This condition is brought on by an increase in cytosine-adenine-guanine repeats in the huntingtin (Htt) gene on chromosome-4, which produces the Htt protein's poly-glutamine (poly-Q). Despite significant progress...Read more
NCBI-Aggregator
HDinHD > NCBI-Aggregator
